David Zahrieh

7PUBLICATIONS
52CO-AUTHORS
ChemotherapyMolecular targetsCancer geneticsCancer therapy (excl. chemotherapy and radiation therapy)Predictive and prognostic markers
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (7)

|May 27, 2026
Placebo Response in Phase II-III Symptom Intervention Studies: A Focus on Chemotherapy-Induced Peripheral Neuropathy and Associated Neuropathic Pain.

|Apr 29, 2026
Alliance A221805: Duloxetine to Prevent Oxaliplatin-Induced Chemotherapy-Induced Peripheral Neuropathy: A Randomized, Double-Blind, Placebo-Controlled Phase II Study.

|Feb 11, 2026
Impact of a web-based breast cancer surgery decision aid on knowledge and perceptions of feeling informed in clinics that care for socioeconomically disadvantaged patients: An Alliance Clinical Trial (A231701CD).

Jessica R Schumacher, Bret M Hanlon, David Zahrieh

|Apr 15, 2025
Neoadjuvant cobimetinib and atezolizumab with or without vemurafenib for stage III melanoma: outcomes and the impact of the microbiome from the NeoACTIVATE trial.

Matthew S Block, Garth D Nelson, Jun Chen

|Sep 07, 2023
Electronic Patient-Reported Outcome Data Collection Systems in Oncology Clinical Trials: A Survey of Clinical Research Professionals (an Alliance Study).

Youmin Cho, Ellen M Lavoie Smith, David Zahrieh

|Apr 05, 2023
A five arm natural history study of nasal vestibulitis.

Elizabeth J Cathcart-Rake, David Zahrieh, Deanne Smith

Pageof 2

Frequent Collaborators

3 joint publications

Ellen M Lavoie Smith

2 joint publications

Charles Loprinzi

2 joint publications

Kathryn Ruddy

2 joint publications

Minji Lee